The PSY-PGx Work Program includes a Clinical Study in real-life healthcare settings, which is planned to be conducted at seven international clinical centers. The follow-up duration per patient will be 24 weeks.
Patients planning to change medication due to either adverse effects or inefficacy will be asked to participate in this Clinical Study.
Patients with mood disorder, anxiety disorders or psychotic disorder will be randomised into a group receiving pharmacotherapy treatment as usual or a group receiving pharmacotherapy based on genotyping (PGx). In these groups the psychopharmaca to be studied are sertraline and escitalopram for individualized being treated for mood or anxiety disorders, and aripiprazole or risperidone for psychotic disorders. These drugs were selected because that they have PGx dosing recommendations that are different that the more common used dosages. The primary endpoint of the Clinical Study will be patient recovery, but the study will also include passive monitoring of participants via their smartphones.
If desired, individualized PGx medication advice will be made available to all patients after the study.
DNA will be collected from all participating individuals to build a resource for secondary research.